» Articles » PMID: 26030710

Drugging Plk1: An Attractive Approach to Inhibit Androgen Receptor Signaling

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2015 Jun 2
PMID 26030710
Citations 2
Authors
Affiliations
Soon will be listed here.
Citing Articles

The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan.

Gasimli K, Raab M, Becker S, Sanhaji M, Strebhardt K J Cancer. 2022; 13(3):728-743.

PMID: 35154442 PMC: 8824877. DOI: 10.7150/jca.66492.


Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss G, Jameson G, Von Hoff D, Valsasina B, Davite C, Di Giulio C Invest New Drugs. 2017; 36(1):85-95.

PMID: 28726132 DOI: 10.1007/s10637-017-0491-7.

References
1.
Strebhardt K, Ullrich A . Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30. DOI: 10.1038/nrc1841. View

2.
Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E . Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun. 2011; 2:395. PMC: 3144583. DOI: 10.1038/ncomms1395. View

3.
Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R . Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-82. PMC: 4075966. DOI: 10.1038/nature13229. View

4.
Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S . Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate. 2013; 73(12):1352-63. PMC: 3720713. DOI: 10.1002/pros.22683. View

5.
Raab M, Kramer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dotsch C . Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. Mol Oncol. 2014; 9(1):140-54. PMC: 5528686. DOI: 10.1016/j.molonc.2014.07.020. View